HL-1186 placebo
Phase 2
HL-1186 placebo is one of 48 therapeutic programs targeting Post Operative Pain. It is currently in Phase 2.
2
Indications
3
Total Trials
3
Active Trials
47
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
64 competitors in Post Operative Pain
#DrugCompanyPhaseTrials
1Marcaine
IInnocoll
Approved
Advil
KKenvue Brands
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Ketalar
AAultman Health Foundation
Approved
Oxycontin
PProtega
Approved
Epsom Salt
FFresenius Kabi USA, LLC
Approved
Suboxone
IIndivior Inc.
Approved
EXPAREL
Pacira Pharmaceuticals, IncApproved
Cyklokapron
JJ Molner
Phase 3
Bupivacain
IIstanbul University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Post Operative Pain2 trials
Post Herpetic Neuralgia (PHN)1 trial
A Clinical Trial to Evaluate the Efficacy and Safety of HL-1186 Tablet in the Treatment of Postherpetic Neuralgia
Recruiting·SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.·Phase 2·NCT07758920·200 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for HL-1186 placebo. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]